Nelson Castro

Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial

Philippe Moreau, Meletios Α. Dimopoulos, Joseph Mıkhael et al. · The Lancet · 2021 · 366 citations

Hematological Malignancy, Relapsed Multiple Myeloma, Medicine +11

Rituximab biosimilar and reference rituximab in patients with previously untreated advanced follicular lymphoma (ASSIST-FL): primary results from a confirmatory phase 3, double-blind, randomised, controlled study

Wojciech Jurczak, Ilídia Moreira, Govind Babu Kanakasetty et al. · The Lancet Haematology · 2017 · 79 citations · Full text

Lymphoid Neoplasia, Rituximab Biosimilar, Oncology +8

Lower socioeconomic status is independently associated with shorter survival in Hodgkin Lymphoma patients—An analysis from the Brazilian Hodgkin Lymphoma Registry

Irène Biasoli, Nelson Castro, Márcia Torresan Delamain et al. · International Journal of Cancer · 2017 · 33 citations · Full text

Treatment outcomes for Hodgkin lymphoma: First report from the Brazilian Prospective Registry

Irène Biasoli, Nelson Castro, Marcia Delamain et al. · Hematological Oncology · 2017 · 23 citations

Six cases of leprosy associated with allogeneic hematopoietic SCT

Fabiano Pieroni, Ana Beatriz P. L. Stracieri, Daniela A. Moraes et al. · Bone Marrow Transplantation · 2007 · 15 citations · Full text

Leprosy, Autoimmune Disease, Six Cases +7